ETFs StemRIM

4599

JP3399690001

Pharmaceuticals

Market Closed - Japan Exchange 10:30:00 23/10/2026 +04			5-day change	1st Jan Change
148.00 ^JPY	+2.07%		-9.76%	-43.73%

10-07	StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in USA	CI
09-25	StemRIM Inc. Announces Patent Registration In South Korea For Use Of Redasemtide As Additional Therapeutic Indication Of Cartilage Disorders	CI

ETFs positioned on StemRIM

Name		YTD change	Weight	AuM
ISHARES INTERNATIONAL SMALL-CAP EQUITY FACTOR ETF - USD		+4.87%	0.01%	679 M€

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Companyâ€™s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Employees

Sector

Pharmaceuticals

More about the company